BeOne Medicines Ltd. (ONC) generates a steady flow of oncology news that reflects its focus on hematology and solid tumors. As a Switzerland‑domiciled global oncology company with listings on NASDAQ, the Hong Kong Stock Exchange and the STAR Market in Shanghai, BeOne regularly issues updates on clinical data, regulatory milestones, financial performance and corporate developments.
Investors and healthcare professionals following ONC news will see frequent announcements related to B‑cell malignancies, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The company highlights new data for its BTK inhibitor BRUKINSA, including long‑term results from Phase 3 trials such as SEQUOIA and ALPINE, as well as patient‑reported outcomes and guideline updates. News also covers sonrotoclax, an investigational BCL2 inhibitor, with items on FDA Breakthrough Therapy Designation, Priority Review for relapsed or refractory MCL, and clinical results in CLL and other B‑cell cancers. Updates on BTK degrader BGB‑16673 from the CaDAnCe clinical program appear alongside these hematology releases.
On the solid tumor side, BeOne’s news includes Phase 3 trial results for ZIIHERA (zanidatamab) plus TEVIMBRA (tislelizumab) and chemotherapy in first‑line HER2‑positive gastroesophageal adenocarcinoma, as well as regulatory plans based on these data. Additional releases describe TEVIMBRA’s expanding indications and BGB‑B2033’s FDA Fast Track Designation in hepatocellular carcinoma. Financial news items provide quarterly revenue, product sales trends for BRUKINSA and TEVIMBRA, cash flow metrics and updated guidance, while corporate updates cover conference presentations, research milestones and agreements such as the IMDELLTRA royalty purchase arrangement with Royalty Pharma.
For users tracking ONC, this news stream offers insight into BeOne’s evolving hematology and solid tumor portfolios, its regulatory interactions in major markets and its stated goal of broadening patient access to cancer therapies. Bookmarking the ONC news page on Stock Titan allows readers to follow company press releases, clinical milestones and financial disclosures in one place.
BeOne Medicines (NASDAQ: ONC) will participate in the Jefferies Global Healthcare Conference in London on November 17, 2026. Its fireside chat is scheduled for 9:30 a.m. GMT. A live webcast will be accessible through the investor section at https://ir.beonemedicines.com, with an archived webcast available on the company’s website.
BeOne Medicines (ONC) presented early-stage liver and lung cancer trial results and a Phase 3 breast cancer study update at ESMO 2026. BGB-B2033 produced a 36.0% confirmed objective response rate, measuring tumor shrinkage, at its recommended Phase 3 dose in liver cancer. The estimated six-month confirmed response-duration rate was 74.1%. BeOne plans global registrational trials by the end of 2026.
In lung cancer, BGB-58067 achieved a 25.3% confirmed response rate among 75 evaluable patients with MTAP-deficient disease. Preliminary BG-C477 results showed a 56.0% confirmed response rate in patients with high CEA expression. Both programs are intended to advance toward late-stage development in 2027. Severe adverse events occurred in each program. The Phase 3 KANDELA-302 breast cancer trial began enrollment in May 2026, comparing BGB-43395 plus letrozole with selected CDK4/6 inhibitors plus letrozole.
BeOne Medicines (ONC) reported updated Phase 3 survival results for TEVIMBRA plus ZIIHERA and chemotherapy in first-line HER2-positive advanced gastroesophageal cancer. After 35.3 months of follow-up in HERIZON-GEA-01, median overall survival was 27.0 months with the combination versus 19.6 months with trastuzumab plus chemotherapy. Estimated survival at 36 months was 39.8% versus 22.9%.
ZIIHERA plus chemotherapy achieved median overall survival of 22.9 months, meeting the remaining primary endpoint versus trastuzumab plus chemotherapy. Adding TEVIMBRA to ZIIHERA plus chemotherapy was associated with longer survival but did not reach statistical significance in an underpowered analysis (P=0.0502). Both experimental regimens improved progression-free survival versus trastuzumab plus chemotherapy. No new safety signals emerged; diarrhea was the most common severe treatment-related adverse event.
BeOne Medicines (ONC) will report its third quarter 2026 financial results on November 5, 2026, before financial markets open.
Management will host a live webcast at 8:00 a.m. ET following the results release. The webcast will be accessible through the company’s investor website, where an archived version will also be available.
BeOne Medicines (ONC) will present solid tumor pipeline and TEVIMBRA data at the ESMO Congress on October 23–27, 2026, in Madrid.
Presentations cover four investigational programs: Phase 1 liver cancer data for BGB-B2033, first-in-human data for BG-C477 and BGB-58067, and the ongoing Phase 3 KANDELA-302 breast cancer trial of BGB-43395. Seven TEVIMBRA abstracts include the second interim analysis of HERIZON-GEA-01, evaluating ZIIHERA plus chemotherapy, with and without TEVIMBRA, in first-line HER2-positive advanced or metastatic gastroesophageal adenocarcinoma. Other analyses address lung, gastric and esophageal cancers. No numerical clinical results are disclosed in this announcement.
BeOne Medicines (NASDAQ: ONC) announced it will participate in the Morgan Stanley Annual Global Healthcare Conference on September 14, 2026, featuring a fireside chat at 11:30 a.m. EDT. A live and archived webcast will be available in the investors section of the company’s website.
BeOne Medicines (Nasdaq: ONC) announced a voluntary agreement with the U.S. government to expand American patients’ access to its innovative cancer medicines and strengthen its U.S. manufacturing base. The agreement includes participation in the GENEROUS Model and a commitment to price future FDA-approved products in line with other key developed markets.
According to BeOne, the company secured an exemption from Section 232 pharmaceutical tariffs through an onshoring agreement, supported by a recently announced $300 million investment in its Hopewell, NJ facility, bringing total U.S. manufacturing investment to more than $1 billion. The expansion will add small-molecule capacity and about 120 full-time jobs, supporting a pipeline of over 35 clinical- and commercial-stage assets and 93 clinical trials at around 1,100 U.S. sites.
BeOne Medicines (Nasdaq: ONC) reported positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial in first-line HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). ZIIHERA (zanidatamab) plus chemotherapy showed a statistically significant and clinically meaningful overall survival (OS) improvement versus trastuzumab plus chemotherapy, meeting the remaining primary OS endpoint.
IA2 also showed an improved OS hazard ratio and durable outcomes for the TEVIMBRA (tislelizumab) + ZIIHERA + chemotherapy regimen, with a generally manageable safety profile and no new safety signals. According to BeOne Medicines, FDA sBLA approvals on August 25, 2026 made these regimens the first immunotherapy-based first-line option in this setting with median OS exceeding two years, regardless of PD-L1 status.
BeOne Medicines (Nasdaq: ONC) announced that the U.S. FDA approved a supplemental Biologics License Application for TEVIMBRA (tislelizumab) in combination with ZIIHERA (zanidatamab) and chemotherapy as first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA).
The approval is based on Phase 3 HERIZON-GEA-01 data, where the regimen achieved median overall survival of 26.4 months vs 19.2 months and median progression-free survival of 12.4 vs 8.1 months versus trastuzumab plus chemotherapy. Benefits were observed regardless of PD-L1 status and across HER2 expression levels, with safety consistent with known profiles and no new safety signals identified.
BeOne Medicines (Nasdaq: ONC), the BeOne Care Foundation and The Max Foundation renewed their partnership through 2028 to expand access to BRUKINSA® (zanubrutinib) for chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support about 1,000 patients cumulatively.
Since launching in 2023, the collaboration has enabled access for more than 300 CLL patients in Armenia, Ethiopia and Nepal, exceeding the original scope by roughly 150 patients. BeOne Medicines is donating BRUKINSA, while the BeOne Care Foundation is providing a $1 million grant over two years for patient care, physician engagement and operational infrastructure. The renewed agreement maintains support in existing countries and may extend to Côte d’Ivoire, Malawi, Mongolia, Mozambique, Togo and Zambia, with patients able to continue treatment beyond the partnership term as medically needed.